CTOs on the Move

Sensus Healthcare

www.sensushealthcare.com

 
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive, and cost-effective treatments for both oncological and non-oncological conditions. Offering proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world. The Sculptura™ robotic radiation oncology system provides targeted intraoperative triple-modulated radiotherapy (IORT) and Brachytherapy ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Emiliano Sosa
 Chief Technical Officer Profile

Funding

Sensus Healthcare raised $15M on 09/17/2018

Similar Companies

Akeso Care Management

Akeso Care Management is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Hilco/Wilson Smart Optical Solutions

Hilco/Wilson Smart Optical Solutions is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Plainville, MA. To find more information about Hilco/Wilson Smart Optical Solutions, please visit www.hilco-usa.com

CME Outfitters

CME Outfitters is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amanna Health Institute

Amanna Health Institute is a Alpena, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elcelyx Therapeutics

lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.